© BusinessWire
14.07.2025
SLP
LISTED
NASDAQ
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025.
Third Quarter 20...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
DFTX
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grants
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 96,400 common s...
Themefolio
Profiler
Peergroup
© ActuNews
14.07.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – July 14, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on July 9, 2025, from Atlas Sp...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ActuNews
14.07.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 14 juli 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transparan...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
14.07.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone
News Preview
STOCKHOLM, SWEDEN – July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 24.6 million through a convertible loan to be used for the ongoing clinical Phase 1b/2a study of golexanolone in primary biliary cholangitis. The convertible loan with attached share opti...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.07.2025
ORY
LISTED
BME
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
News Preview
MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office fo...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.07.2025
CELC
LISTED
NASDAQ
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042
News Preview
MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.07.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin
News Preview
STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part 1 of its ongoing clinical phase 2a study with sevuparin, which is being evaluated as a treatment for patients with chronic kidney disease with anemia....
Themefolio
Profiler
Peergroup
© BusinessWire
11.07.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.07.2025
ILM1
LISTED
XETR
Medios schließt öffentliches Aktienrückkaufangebot erfolgreich ab
News Preview
NICHT ZUR WEITERLEITUNG ODER VERBREITUNG, WEDER DIREKT NOCH INDIREKT, IN ODER INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN ODER JAPAN ODER ANDEREN JURISDIKTIONEN, IN DENEN DIE WEITERLEITUNG ODER VERBREITUNG RECHTSWIDRIG WÄRE. ES GELTEN WEITERE BESCHRÄNKUNGEN. BITTE BEACHTEN SIE DEN WICHTIGEN HINWEIS AM ENDE DIESER PRESSEMITTEIL......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.07.2025
ILM1
LISTED
XETR
Medios successfully completes public share buyback offer
News Preview
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTE AT THE END OF THIS PRESS RELEASE.
Press release
Medios successfully c......
Themefolio
Profiler
Peergroup
© ActuNews
10.07.2025
ALTHX
LISTED
EURONEXT
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 JUIN 2025
News Preview
Lyon, France – 10 juillet 2025, 18h00 CET - Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, annonce aujourd'hui la publication de sa position de trésorerie au 30 juin 2025.
Au 30 juin 2025, la trésorerie disponible s'établit à 2,1 M€ co...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ActuNews
10.07.2025
ALTHX
LISTED
EURONEXT
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2025
News Preview
Lyon, France – 10 July 2024, 6.pm CET – Theranexus, a biopharmaceutical company developing drug candidates for rare neurological diseases, today published its cash position as of 30 June 2025.
On 30 June 2025, total available funds stood at €2.1 M, compared with €2.9 million on 31 March 2025. In addition, a payment...
Themefolio
Profiler
Peergroup
© ActuNews
10.07.2025
OXUR
LISTED
EURONEXT
Oxurion kondigt het vervullen van de tweede opschortende voorwaarde aan in de overname van Axiodis
News Preview
Leuven, BELGIË – 10 juli 2025 – 17u45 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt aan dat de tweede opschortende voorwaarde in het kader van de overname van 72% van het kapitaal van Axiodis CRO door haar Franse dochteronderneming is vervuld.
Het Franse ministerie...
Themefolio
Profiler
Peergroup
© ActuNews
10.07.2025
OXUR
LISTED
EURONEXT
Oxurion Announces the Fulfilment of the Second Condition Precedent in the Acquisition of Axiodis
News Preview
Leuven, BELGIUM – July 10, 2025 at 5:45 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces the fulfilment of the second condition precedent in the acquisition of 72% of the share capital of Axiodis CRO by its French subsidiary.
The French Ministry for the Economy, Finance and Industrial and Di...
Themefolio
Profiler
Peergroup
© ActuNews
10.07.2025
OXUR
LISTED
EURONEXT
Oxurion annonce la levée de la seconde condition suspensive dans l'acquisition d'Axiodis
News Preview
Louvain, BELGIQUE – 10 juillet 2025 – 17h45, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce la levée de la seconde condition suspensive dans le cadre de l'acquisition de 72 % du capital d'Axiodis CRO par sa filiale française.
Le ministère de l...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2025 financial results and provide recent corporate updates on August 7, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT).
Conference Call and Webcast...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2025
GXI
LISTED
XETR
Umsatz- und Ergebnissprung durch Bormioli Pharma, weiterhin Markteinflüsse im operativen Geschäft
News Preview
Gerresheimer im 1. HJ 2025: Umsatz- und Ergebnissprung durch Bormioli Pharma, weiterhin Markteinflüsse im operativen Geschäft
1. HJ 2025: Umsatz +15,7 %, Adjusted EBITDA +11,8 %
Rückkehr zu organischem Umsatzwachstum in Q2
Organische Entwicklung gegenüber Pro-Forma-Zahlen 1. HJ 2024: Umsatz -2,1 %, Adjusted EBITDA -6,4%
Gedämpfte Marktnachfrage......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2025
GXI
LISTED
XETR
Bormioli Pharma boosts revenues and earnings, continued market influences in operating business
News Preview
Gerresheimer in H1 2025: Bormioli Pharma boosts revenues and earnings, continued market influences in operating business
H1 2025: Revenue +15.7%, adjusted EBITDA +11.8%
Return to organic revenue growth in Q2
Organic development compared to pro forma figures for H1 2024: Revenue -2.1%, adjusted EBITDA -6.4%
Subdued demand in the cosmetics and or......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2025
FYB
LISTED
XETR
Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
News Preview
Press Release // July 10, 2025
Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
Streamlined clinical development program, which no longer requires a Phase III trial, is already in a far advanced stage
Last patient enrolled in Dahlia pharmacokinetic (PK) study (Last P......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2025
FYB
LISTED
XETR
Formycon schließt Patientenrekrutierung für die klinische Entwicklung des Keytruda®-Biosimilar-Kandidaten FYB206 erfolgreich ab
News Preview
Pressemitteilung // 10. Juli 2025
Formycon schließt Patientenrekrutierung für die klinische Entwicklung des Keytruda®-Biosimilar-Kandidaten FYB206 erfolgreich ab
Optimiertes klinisches Entwicklungsprogramm, das ohne Phase-III-Studie auskommt, bereits sehr weit fortgeschritten
Letzter Patient in Dahlia-Pharmakokinetik-Studie (PK-Studie) einge......
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
LIVN
LISTED
NASDAQ
LivaNova to Announce Second-Quarter 2025 Results
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2025 results prior to the call.
The audiocast will be accessible at www.livanova....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
BAVA
LISTED
CPH
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country
News Preview
COPENHAGEN, Denmark, July 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued over DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a European country. This is another larger order in recent years from the country to strengthen national preparedness against biological threats and epidemics like sma...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
ORNBV
LISTED
HEL
Inside information: Orion upgrades full-year outlook for 2025
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 9 JULY 2025 at 13.00 EEST ...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.07.2025
AGFB
LISTED
EURONEXT
AGFA HealthCare Achieves HITRUST I1 Certification, Demonstrating Its Commitment to and Compliance With Data Protection Standards, and Protecting Against Cybersecurity Threats
News Preview
HITRUST certification validates that AGFA HealthCare is operating using leading security practices to protect sensitive information. MORTSEL, BE / ACCESS Newswire / July 9, 2025 / AGFA HealthCare, a leading provider of Imaging IT, today announced that its Enterprise Imaging Solutions earned certified status by HITRUST for information security.AGFA...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
GNFT
LISTED
EURONEXT
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
CELC
LISTED
NASDAQ
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
News Preview
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. gove...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
CELC
LISTED
NASDAQ
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
News Preview
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. gove...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
TEM
LISTED
NASDAQ
Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of patients across its network of provider sites, helpi...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
CYRX
LISTED
NASDAQ
Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers
News Preview
New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology
NASHVILLE, Tenn., July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of MVE Biological S...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
INDV
LISTED
NASDAQ
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
News Preview
RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
POAI
LISTED
NASDAQ
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
News Preview
PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement (“SEPA”) with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”). Predictive Oncology expects the partnershi...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
OGI
LISTED
NASDAQ
Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share, announced today that its recently acquired beverage business, Collective Project, has launched an e-commerce platform in the U.S. marking a key milestone in the Company’s strategic expansion into the rapidly evolving U.S....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.07.2025
JAGX
LISTED
XNMS
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indic
News Preview
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that an access and benefit sharing agreement focused on two cultivated species of the coca plant - Eryth...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
HNSA
LISTED
STO
Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
News Preview
LUND, Sweden, July 8, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.
Dr Philipson has over 25 years of industry...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
HNSA
LISTED
STO
Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
News Preview
LUND, Sweden, July 8, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.
Dr Philipson has over 25 years of industry...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.07.2025
SN
LISTED
LSE
Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle. ...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
ICLR
LISTED
NASDAQ
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company’s leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer...
Themefolio
Profiler
Peergroup
© PR Newswire
07.07.2025
SECT_B
LISTED
STO
One of the largest multi-region healthcare systems in the US expands enterprise imaging cloud service from Sectra with pathology to leverage integrated diagnostics in cancer care
News Preview
LINKÖPING, Sweden and SHELTON, Conn., July 7, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) module for digital pathology will be used by a US-based health system serving a multi-million strong patient community. This is an expansion of the healthcare provider's usage of Sectra's enterprise...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.07.2025
NSIS B
LISTED
CPH
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
News Preview
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe...
Themefolio
Profiler
Peergroup
© BusinessWire
04.07.2025
HLN
LISTED
LSE
Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre
News Preview
This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon’s science capabilities, accelerate innovation, and serve as a centre of excellence for gl...
Themefolio
Profiler
Peergroup
© ActuNews
04.07.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© ActuNews
04.07.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 4 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 100.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.07.2025
ORNBV
LISTED
HEL
Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025
News Preview
ORION CORPORATION PRESS RELEASE 4 JULY 2025 at 09.00 EEST ...
Themefolio
Profiler
Peergroup
© ActuNews
03.07.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – July 3, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on July 3, 2025, from Atlas Spe...
Themefolio
Profiler
Peergroup
© ActuNews
03.07.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 3 juli 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transparant...
Themefolio
Profiler
Peergroup
© PR Newswire
03.07.2025
VITR
LISTED
STO
Invitation to Vitrolife Group's presentation of the Q2 2025 interim report
News Preview
GOTHENBURG, Sweden, July 3, 2025 /PRNewswire/ -- Vitrolife AB (publ) will publish its Q2 2025 interim report on Thursday, 17 July 2025 at 08:00 am CEST. A conference call for investors, analysts and financial media will be held at 10:00 am CEST the same day.
The presentation will be held in English by Bronwyn Brophy O'Connor, CEO, and Helena Wen...
Themefolio
Profiler
Peergroup
© PR Newswire
03.07.2025
SECT_B
LISTED
STO
Sectra publishes Annual Report and Sustainability Report for 2024/2025
News Preview
LINKÖPING, Sweden, July 3, 2025 /PRNewswire/ -- Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2024/2025 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The documents are attached to this press release and are al...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
KDEV
LISTED
STO
Karolinska Development receives update from Organon concerning OG-6219
News Preview
STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical d...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© PR Newswire
02.07.2025
HIK
LISTED
LSE
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
News Preview
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment
LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name TYZAVAN™ (Va...
Themefolio
Profiler
Peergroup
© PR Newswire
02.07.2025
SOBI
LISTED
STO
Invitation: Sobi's Q2 report
News Preview
Sobi plans to publish its report for the second quarter of 2025 on 16 July 2025 at 08:00 CEST.
STOCKHOLM, July 2, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST, 13:00 GMT, and 08:00 EST. The call will include a presentation of the results and a Q&A session.
The presenta...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
TIL
LISTED
NASDAQ
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
News Preview
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
News Preview
OSE Immunotherapeutics provides an update on ongoing proceedings...
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2025
SRT3
LISTED
XETR
Sartorius completes acquisition of MatTek
News Preview
Göttingen, Germany | July 1, 2025
Sartorius completes acquisition of MatTek
The life science group Sartorius has successfully closed the acquisition of MatTek Corp, including Visikol Inc, from the Swedish BICO Group AB, as announced in April. The acquisition was completed on July 1, 2025, following the receipt of the required regulatory approval an......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2025
SRT3
LISTED
XETR
Sartorius schließt Akquisition von MatTek ab
News Preview
Göttingen | 1. Juli 2025
Sartorius schließt Akquisition von MatTek ab
Der Life-Science-Konzern Sartorius hat die im April angekündigte Übernahme der MatTek Corp. einschließlich der Visikol Inc. von der schwedischen BICO Group AB erfolgreich abgeschlossen. Die Akquisition erfolgte nach Erhalt der behördlichen Genehmigung und Erfüllung anderer üblich......
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
SOBI
LISTED
STO
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
News Preview
STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone pay...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
SOBI
LISTED
STO
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
News Preview
STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone pay...
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2025
FYB
LISTED
XETR
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
News Preview
Press Release // July 1, 2025
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
Partnership marks a landmark step towards global availability of FYB201
Bio Usawa gets exclusive rights to register and commercialize FYB201/BioUcenta™1 in Sub-Saharan Africa
Product launch expected in ......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2025
FYB
LISTED
XETR
Bio Usawa wird Vermarktungspartner von FYB201/ BioUcenta™ (Ranibizumab) in der Region Subsahara-Afrika
News Preview
Pressemitteilung // 1. Juli 2025
Bio Usawa wird Vermarktungspartner von FYB201/ BioUcenta™ (Ranibizumab) in der Region Subsahara-Afrika
Partnerschaft markiert einen Meilenstein auf dem Weg zur globalen Verfügbarkeit von FYB201
Bio Usawa erhält exklusive Rechte zur Zulassung und Vermarktung von FYB201/BioUcenta™1 in der Region Subsahara-Afrika
......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
